Bajaj Finserv Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹11.36-0.91%
17 Jul 2026
Loading…
| Asset | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Equity | 96.15% | 95.80% | 96.71% | 94.75% | 97.52% | 95.11% |
| Debt | 2.96% | 3.06% | 3.25% | 1.78% | 2.37% | 1.75% |
| Others (incl. cash) | 0.89% | 1.14% | 0.04% | 3.47% | 0.11% | 3.14% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | Healthcare | 45,227 | 29.75 | 8.40% | -0.67%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 27,355 | 23.75 | 6.71% | -0.02%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 1,46,132 | 23.07 | 6.52% | 0.35%↑ |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 1,20,824 | 22.5 | 6.36% | -0.18%↓ |
| Piramal Pharma Ltd. | Healthcare | 12,71,805 | 21.38 | 6.04% | -0.47%↓ |
| Rubicon Research Ltd. | Healthcare | 1,51,995 | 21.32 | 6.02% | 1.50%↑ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 40,333 | 18.63 | 5.26% | 0.00% |
| Neuland Laboratories Ltd. | Healthcare | 8,742 | 16.24 | 4.59% | 0.20%↑ |
| Emcure Pharmaceuticals Ltd. | Healthcare | 84,054 | 15.43 | 4.36% | 0.18%↑ |
| Max Healthcare Institute Ltd. | Healthcare | 1,30,366 | 14.72 | 4.16% | 0.48%↑ |
| Fortis Healthcare Ltd. | Healthcare | 1,20,183 | 11.5 | 3.25% | -0.11%↓ |
| Zydus Wellness Ltd. | Consumer Staples | 1,73,510 | 9.98 | 2.82% | 0.17%↑ |
| Ipca Laboratories Ltd. | Healthcare | 50,483 | 8.59 | 2.43% | 0.12%↑ |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 61,718 | 8.35 | 2.36% | -0.07%↓ |
| Senores Pharmaceuticals Ltd. | Healthcare | 60,946 | 8.11 | 2.29% | 0.24%↑ |
| Navin Fluorine International Ltd. | Chemicals | 10,000 | 7.69 | 2.17% | 0.03%↑ |
| Laurus Labs Ltd. | Healthcare | 50,000 | 7.59 | 2.14% | 0.09%↑ |
| Shaily Engineering Plastics Ltd. | Materials | 24,809 | 7.18 | 2.03% | -0.20%↓ |
| Sanofi Consumer Healthcare India Ltd. | Healthcare | 13,863 | 6.37 | 1.80% | -0.11%↓ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 27,743 | 6.12 | 1.73% | -0.17%↓ |
| Sector | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 86.77% | 86.16% | 86.32% | 85.04% | 85.67% | 80.82% |
| Consumer Staples | 2.82% | 2.65% | 5.27% | 4.95% | 7.14% | 7.40% |
| Chemicals | 2.17% | 2.14% | 2.11% | 2.05% | 1.99% | - |
| Materials | 2.03% | 2.23% | 1.94% | 1.72% | 1.54% | 1.54% |
| Services | 1.04% | 1.12% | 1.07% | 0.99% | 1.18% | 5.35% |
| Financial | 1.00% | - | - | - | - | - |
| Capital Goods | 0.32% | 0.59% | - | - | - | - |
| Insurance | - | 0.91% | - | - | - | - |
26.9 / 100
Weighted average Value score is 26.9. This indicates that portfolio is relatively reasonably valued using composite of value measures.
74.0 / 100
Weighted average Price Momentum score is 74.0. This indicates that portfolio has average momentum using composite of momentum measures.
84.1 / 100
Weighted average Quality score is 84.1. This indicates that portfolio has high quality using composite of quality measures.
70.9 / 100
Weighted average QVM score is 70.9. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.